Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27098055 | 1.00 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBPIK3CGACACB | |
| SCHEMBL29547397 | 1.00 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBPIK3CGACACB | |
| SCHEMBL27098057 | 0.85 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGACACB | |
| SCHEMBL27139547 | 0.85 | ACACB (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGACACB | |
| SCHEMBL29547656 | 0.85 | ACACB (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGACACB | |
| SCHEMBL27098053 | 0.85 | ACACB (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGACACB | |
| SCHEMBL20129074 | 0.83 | GRIN2B (0.35) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL20120826 | 0.82 | TDO2 (0.38) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20120825 | 0.82 | TDO2 (0.38) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29547432 | 0.82 | TDO2 (0.38) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | PIK3CD 2740/4885PIK3CA 2655/4885PIK3CB 2089/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | PIK3CD 2235/4885PIK3CA 2277/4885PIK3CB 1659/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | PIK3CD 2740/4885PIK3CA 2655/4885PIK3CB 2089/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | PIK3CD 3339/4885PIK3CA 3619/4885PIK3CB 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.